Ezetimibe, which is a drug that inhibits the absorption of FC in the small intestine, is able to decrease ALT levels, and suppress hepatic injury in NAFLD subjects. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.